Gaithersburg, MD, June 28, 2002-- MedImmune, Inc.'s (NASDAQ: MEDI) second quarter 2002 financial results will be released on Thursday, July 25, 2002 before the opening of the U.S. financial markets. The company will also host a conference call and live audio webcast at 8:00 a.m. EDT following the announcement. During the conference call, MedImmune's management will discuss the financial results and other business for the quarter.
The press release and the live webcast can be accessed by going to the Investor Relations section of the MedImmune website at http://www.medimmune.com. Following the webcast, an archived version of the call will be available at the same address until
August 1, 2002.
MedImmune is a leading biotechnology company focused on researching, developing and commercializing products to prevent or treat infectious disease, autoimmune disease and cancer. MedImmune currently markets three products, Synagis® (palivizumab), Ethyol® (amifostine) and CytoGam® (cytomegalovirus immune globulin intravenous (human)), and has 11 products in clinical testing. MedImmune employs approximately 1,500 people, is headquartered in Gaithersburg, Maryland, and has additional operations in Frederick, Maryland, as well as Pennsylvania, California, the United Kingdom and the Netherlands. For more information on MedImmune, visit the company's website at www.medimmune.com
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. MedImmune cautions that RSV disease occurs primarily during the winter months; the company believes its operating results will reflect that seasonality for the foreseeable future. The company is also developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.